- Kyowa Kirin’s full-year net income forecast is 57 billion yen, missing the estimated 73.06 billion yen.
- The company projects net sales of 478 billion yen, below the estimated 500.57 billion yen.
- Kyowa Kirin expects a dividend of 60 yen, slightly above the estimate of 59.20 yen.
- For the fourth quarter, net income was 3.97 billion yen, an 86% decrease year-over-year, missing the projected 14.41 billion yen.
- Fourth-quarter net sales reached 132.76 billion yen, a 2.5% year-over-year decline, surpassing the estimate of 129.16 billion yen.
- In 2024, net income totaled 59.87 billion yen, marking a 26% decrease year-over-year, falling short of the 69.56 billion yen estimate.
- The core operating profit for the year stood at 95.41 billion yen, a slight 1.4% decrease year-over-year.
- Annual net sales were 495.56 billion yen, a 12% increase year-over-year, beating the estimated 490.87 billion yen.
- Investment analysts have issued 7 buy recommendations, 6 hold recommendations, and 0 sell recommendations for the company.
Kyowa Kirin Co Ltd on Smartkarma
Analyst coverage on Smartkarma by Tina Banerjee sheds light on Kyowa Kirin Co Ltd‘s recent Phase 3 trial results for rocatinlimab in Atopic Dermatitis. The report highlights that while the trial met primary and secondary endpoints, the efficacy data was deemed less compelling compared to rival drugs. This discrepancy resulted in a significant drop in Kyowa Kirin’s shares. The concern over the competitive strength of rocatinlimab has cast a shadow on the company’s outlook, indicating that a recovery for Kyowa Kirin shares might be a gradual process.
The analysis by Tina Banerjee emphasizes the challenges Kyowa Kirin Co Ltd faces in the Atopic Dermatitis market. Despite achieving statistical significance in the Phase 3 trial, the shortcomings in efficacy data have raised doubts about the drug’s competitiveness. This skepticism has led to a bearish sentiment towards Kyowa Kirin’s shares, suggesting that the company may encounter hurdles in regaining market confidence in the near future.
A look at Kyowa Kirin Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Kyowa Kirin Co Ltd has a positive long-term outlook with solid scores in Growth and Resilience. With a Growth score of 4, the company is positioned well for future expansion and development. Additionally, its Resilience score of 4 indicates a strong ability to withstand market challenges and uncertainties, providing a stable foundation for long-term success.
Although Kyowa Kirin Co Ltd shows moderate scores in Value and Dividend at 3 each, its Momentum score of 2 suggests a slightly slower pace in terms of market performance. Overall, the company’s focus on pharmaceuticals, including innovative products developed through genetic recombination technology, positions it well for sustained growth and resilience in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
